Nuo Therapeutics Files 8-K on Officer/Director Changes
Ticker: AURX · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1091596
| Field | Detail |
|---|---|
| Company | Nuo Therapeutics, Inc. (AURX) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $325,000, $290,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election
Related Tickers: NURX
TL;DR
Nuo Therapeutics (NURX) filed an 8-K detailing leadership changes and officer appointments.
AI Summary
Nuo Therapeutics, Inc. filed an 8-K on October 10, 2025, reporting events as of October 7, 2025. The filing indicates changes related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. It also mentions shareholder nominations and other events.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in key personnel and board composition can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Nuo Therapeutics, Inc. (company) — Registrant
- October 7, 2025 (date) — Earliest event reported
- October 10, 2025 (date) — Filing date
FAQ
What specific officer or director positions were affected by the changes reported in the 8-K?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" but does not specify the exact positions in the provided text.
Are there any details regarding new compensatory arrangements for officers mentioned?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not provided in the excerpt.
What is the significance of "Shareholder Nominations Pursuant to Exchange Act Rule 14a-11" being listed?
This suggests that shareholders may have nominated candidates for the board of directors under specific SEC rules, potentially indicating activism or upcoming proxy contests.
What does the "Other Events" item typically entail in an 8-K filing?
The "Other Events" item is a catch-all for material events that do not fit into the other specific categories of an 8-K, requiring disclosure.
What is the company's primary business based on its SIC code?
Nuo Therapeutics, Inc. is classified under SIC code 3841, which corresponds to "Surgical & Medical Instruments & Apparatus."
Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2025-10-10 08:30:10
Key Financial Figures
- $325,000 — r of 2025), the salary of Mr. Jorden is $325,000 and the salary of Mr. Clausen is $290,0
- $290,000 — 25,000 and the salary of Mr. Clausen is $290,000. In approving the salary increases, the
Filing Documents
- aurx20251009_8k.htm (8-K) — 25KB
- 0001437749-25-030813.txt ( ) — 141KB
- aurx-20251007.xsd (EX-101.SCH) — 3KB
- aurx-20251007_def.xml (EX-101.DEF) — 10KB
- aurx-20251007_lab.xml (EX-101.LAB) — 14KB
- aurx-20251007_pre.xml (EX-101.PRE) — 10KB
- aurx20251009_8k_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
01 Other Events
Item 8.01 Other Events. On October 7, 2025, the Board of Directors of Nuo Therapeutics, Inc. (the "Company") determined that the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting") will be held at the Company's principal executive office at 8285 El Rio, Suite 190, Houston, Texas on December 16, 2025, or as otherwise set forth in the Company's notice and proxy statement for the Annual Meeting to be filed no less than 40 days prior to the Annual Meeting. Stockholders of the Company who wish to have a proposal, including nominations of persons for election to the Board of Directors, considered for inclusion in the Company's proxy materials for the Annual Meeting must ensure that such proposal is received by, on or before the close of business on October 20, 2025, which date the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials, and which complies with the requirements of the Amended and Restated By-Laws of the Company (the "By-Laws"). To be eligible for inclusion in the proxy materials for the Annual Meeting, any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission and in the By-Laws. Proposals and notices must be in writing and received by the Company's Secretary, David Jorden, addressed to: Nuo Therapeutics, Inc. Board of Directors, Attn: Secretary, 8285 El Rio, Suite 190, Houston, Texas 77054.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Chief Financial Officer Date: October 10, 2025